Back to List View Graph View

Hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and represents a major global health burden, particularly in regions with high prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.

Where the papers sit

27 papers from the last 6 months study hepatocellular carcinoma directly · updated from PubMed 16 Nov 2026

  • Immune Microenvironment and Immunotherapy

    Immune evasion and treatment resistance are being linked to tumor-cell transcripts, spatial niches, and the gut microbiome. S100A10-associated CD8+ T-cell exhaustion and Bacteroidetes-related immunotherapy resistance point to microenvironmental mechanisms that may guide combination treatment. Neoantigen-encoding transcripts, circulating mRNA variants, and RNA-sequencing workflows push biomarker discovery toward individualized immune targeting. Coumarin-driven NK-cell activation provides a contrasting preclinical route, while transplant allocation remains a clinical boundary.

    7 papers · 25.9%

  • Oxidative Stress in HCC

    Oxidative and mitochondrial stress are recurring routes to HCC cell death and treatment response. p-Coumaric acid, photodynamic therapy, and FeCo nanozyme patches seek to increase ROS or disrupt autophagic flux, whereas β,β-dimethylacrylshikonin impairs TGM2-associated mitophagy. HIF1α-KLF4-driven hemoglobin expression connects mitochondrial adaptation with sorafenib resistance, highlighting NRF2-linked redox defenses as a potential vulnerability. Clinical use of SGLT2 inhibitors with atezolizumab plus bevacizumab adds a safety and supportive-care question, not yet a unified therapeutic direction.

    6 papers · 22.2%

  • AFP and PIVKA-II Biomarkers

    AFP and PIVKA-II are being combined with routine clinical variables to improve early detection and recurrence prediction after resection. Calibration and bootstrap-based models emphasize clinically usable risk estimates rather than single-marker performance. Serum 5′tRF-32-Glu and proteasome subunits PSMA1, PSMA5, and PSMB2 broaden the search for diagnostic and prognostic signals, with links to tumor-infiltrating leukocytes. CRISPR/Cas12a electrochemical sensing points toward faster multiplex biomarker assays, but validation beyond retrospective cohorts remains open.

    5 papers · 18.5%

  • Others — HCC Screening and Treatment

    Machine-learning screening, CDK9 inhibition, exosome-like vesicles, nanozyme therapy, hepatitis B risk, and clinical associations occupy this heterogeneous set. PCLAF and CDK9 emerge as candidate therapeutic targets, while adherence to hepatitis B treatment links prevention with lower HCC risk. Experimental studies test Akt modulation, arsenic chemodynamic therapy, and indole-based inhibitors rather than a shared treatment strategy. The collection has no consistent clinical endpoint or mechanistic direction.

    9 papers · 33.3%

NEW DIRECTION

Hepatocellular carcinoma is presented as the malignant transformation of a long-standing benign liver lesion

The 20-year focal nodular hyperplasia-to-hepatocellular carcinoma case concerns a lesion that had remained radiologically stable for decades before developing into well-differentiated HCC with vascular invasion 42392677Jul. Whereas the other abstracts treat HCC as an established malignancy or as a target for diagnosis, risk prediction, mechanistic study, or therapy, this report assigns it a distinct natural-history role as a possible malignant endpoint of a previously benign FNH-like lesion.

NEW DIRECTION

Hepatocellular carcinoma is presented as a possible cause of a paraneoplastic autoimmune syndrome

The anti-OJ-positive anti-synthetase syndrome case concerns a patient with hepatocellular carcinoma whose muscle weakness and laboratory abnormalities improved after hepatic lobectomy without immunotherapy, suggesting that HCC can function as the trigger of an autoimmune syndrome rather than merely as the disease being detected, prognosticated, or treated 42772928Sep. This expands the role assigned to HCC in the set to that of a potentially causative malignancy whose removal may resolve an associated systemic immune disorder.

Papers

The 27 papers from the last 6 months that study hepatocellular carcinoma directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Immune Microenvironment and Immunotherapy (7)
  1. Bacteroidetes promote hepatocellular carcinoma progression and resistance to immunotherapy. Hepatology communications · 11 Nov 2026 PMID 43013741
  2. Mechanism of Coumarin in the anti-liver cancer activity by promoting NK cell activation. Medical oncology (Northwood, London, England) · 6 Oct 2026 PMID 42837059
  3. Validation of next-generation sequencing-derived circulating mRNA variants as potential diagnostic tools in hepatocellular carcinoma and cholangiocarcinoma. Oncology reports · 18 Sept 2026 PMID 42757462
  4. Multi-omics and spatial transcriptomics reveal that S100A10 drives CD8+ T-cell exhaustion and immune evasion in hepatocellular carcinoma through cPLA2-5-LOX-mediated arachidonic acid metabolism and ferroptosis. International immunopharmacology · 13 Sept 2026 PMID 42732672
  5. Liver transplant allocation by milan criteria may exclude eligible HCC patients without survival benefit - a post-hoc analysis of the SiLVER study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 30 Aug 2026 PMID 42669573
  6. Decoding neoantigen-encoding tumor-specific transcripts unveils a shared target reservoir for immunotherapy in hepatocellular carcinoma. Journal for immunotherapy of cancer · 21 Jul 2026 PMID 42481156
  7. Artificial Gap Junctional Channel Inhibiting the Proliferation of Hepatocellular Carcinoma Cells. Angewandte Chemie (International ed. in English) · 7 Jun 2026 PMID 42251683
Oxidative Stress in HCC (6)
  1. HCE6-mediated photodynamic therapy induces hepatocellular carcinoma cell death via inhibition of autophagic flux. Journal of materials chemistry. B · 18 Sept 2026 PMID 42758539
  2. HIF1α-KLF4 signaling dictates extra-erythrocyte expression of hemoglobin conferring sorafenib resistance in hepatocellular carcinoma. Signal transduction and targeted therapy · 15 Sept 2026 PMID 42744801
  3. p-Coumaric acid inhibits hepatocellular carcinoma through promoting ROS accumulation. Medical oncology (Northwood, London, England) · 10 Sept 2026 PMID 42720830
  4. Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674726
  5. FeCo Dual-Atom Site Nanozyme Hybrid Microneedle Patch with Enhanced Multienzyme Mimetic Activities for Synergistic Antihepatoma Therapy. ACS applied materials & interfaces · 23 Jun 2026 PMID 42333601
  6. β,β-Dimethylacrylshikonin suppresses hepatocellular carcinoma progression through mitochondrial stress and TGM2-associated mitophagy impairment. Phytomedicine : international journal of phytotherapy and phytopharmacology · 23 May 2026 PMID 42176510
AFP and PIVKA-II Biomarkers (5)
  1. 5'tRF-32-Glu promotes hepatocellular carcinoma progression and has diagnostic value in serum. Molecular biology reports · 12 Nov 2026 PMID 43018799
  2. PSMA1, PSMA5, and PSMB2 serve as prognostic biomarkers and are correlated with tumor-infiltrating leukocytes in HCC. Epigenetics · 14 Sept 2026 PMID 42735232
  3. Integrating Abnormal Prothrombin (PIVKA-II), Alpha-Fetoprotein, and Routine Clinical Variables for Early Detection of Hepatocellular Carcinoma. Journal of visualized experiments : JoVE · 26 Aug 2026 PMID 42644494
  4. Ligand-Engineered Mn-Cysteine as a Potent Laccase Mimic for CRISPR/Cas12a Electrochemical Biosensing of Hepatocellular Carcinoma Biomarkers. ACS nano · 18 Aug 2026 PMID 42611239
  5. Prognostic value of PIVKA-II and routine perioperative laboratory indices for recurrence prediction after curative resection of hepatocellular carcinoma. Clinica chimica acta; international journal of clinical chemistry · 10 Jun 2026 PMID 42269741
Others — HCC Screening and Treatment (9)
  1. Discovery and Optimization of Indole-Based CDK9 Inhibitors for Hepatocellular Carcinoma. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018595
  2. Association of 5-hydroxytryptamine 3 receptor antagonists with prognosis in patients with advanced hepatocellular carcinoma: A propensity score-matched study. PloS one · 8 Oct 2026 PMID 42848747
  3. High Treatment Adherence Is Associated With Lower Observed HCC Risk in Patients With Chronic Hepatitis B and Cirrhosis: A Nationwide Claims-Based Cohort Study. Journal of medical virology · 28 Sept 2026 PMID 42803662
  4. Anti-OJ antibody-positive anti-synthetase syndrome associated with hepatocellular carcinoma. BMJ case reports · 22 Sept 2026 PMID 42772928
  5. Multi-omics and artificial intelligence nominate PCLAF as a prognostic and druggable target for hepatitis B virus-associated hepatocellular carcinoma. Cellular signalling · 22 Jul 2026 PMID 42486346
  6. Dark tea-derived exosome-like nanovesicles suppress hepatocellular carcinoma via inhibiting Akt pathway and modulating immune profiles. Phytomedicine : international journal of phytotherapy and phytopharmacology · 9 Jul 2026 PMID 42424676
  7. Can focal nodular hyperplasia transform into hepatocellular carcinoma? A 20-year journey from benign to malignant. BMJ case reports · 2 Jul 2026 PMID 42392677
  8. The Promise of Machine Learning-Based Population Screening for Hepatocellular Carcinoma. Cancer discovery · 1 Jul 2026 PMID 42381462
  9. Valence-activated arsenic nanozyme enables cascade-amplified chemodynamic therapy for hepatocellular carcinoma. International journal of pharmaceutics · 25 Jun 2026 PMID 42349733

By study type

Clinical trials (1)
  1. Liver transplant allocation by milan criteria may exclude eligible HCC patients without survival benefit - a post-hoc analysis of the SiLVER study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 30 Aug 2026 PMID 42669573
Observational studies and case reports (5)
  1. High Treatment Adherence Is Associated With Lower Observed HCC Risk in Patients With Chronic Hepatitis B and Cirrhosis: A Nationwide Claims-Based Cohort Study. Journal of medical virology · 28 Sept 2026 PMID 42803662
  2. Anti-OJ antibody-positive anti-synthetase syndrome associated with hepatocellular carcinoma. BMJ case reports · 22 Sept 2026 PMID 42772928
  3. Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674726
  4. Can focal nodular hyperplasia transform into hepatocellular carcinoma? A 20-year journey from benign to malignant. BMJ case reports · 2 Jul 2026 PMID 42392677
  5. Prognostic value of PIVKA-II and routine perioperative laboratory indices for recurrence prediction after curative resection of hepatocellular carcinoma. Clinica chimica acta; international journal of clinical chemistry · 10 Jun 2026 PMID 42269741
Human data, design not indexed (6)
  1. Association of 5-hydroxytryptamine 3 receptor antagonists with prognosis in patients with advanced hepatocellular carcinoma: A propensity score-matched study. PloS one · 8 Oct 2026 PMID 42848747
  2. Validation of next-generation sequencing-derived circulating mRNA variants as potential diagnostic tools in hepatocellular carcinoma and cholangiocarcinoma. Oncology reports · 18 Sept 2026 PMID 42757462
  3. PSMA1, PSMA5, and PSMB2 serve as prognostic biomarkers and are correlated with tumor-infiltrating leukocytes in HCC. Epigenetics · 14 Sept 2026 PMID 42735232
  4. Integrating Abnormal Prothrombin (PIVKA-II), Alpha-Fetoprotein, and Routine Clinical Variables for Early Detection of Hepatocellular Carcinoma. Journal of visualized experiments : JoVE · 26 Aug 2026 PMID 42644494
  5. Ligand-Engineered Mn-Cysteine as a Potent Laccase Mimic for CRISPR/Cas12a Electrochemical Biosensing of Hepatocellular Carcinoma Biomarkers. ACS nano · 18 Aug 2026 PMID 42611239
  6. The Promise of Machine Learning-Based Population Screening for Hepatocellular Carcinoma. Cancer discovery · 1 Jul 2026 PMID 42381462
Preclinical: animal, cell and lab studies (13)
  1. 5'tRF-32-Glu promotes hepatocellular carcinoma progression and has diagnostic value in serum. Molecular biology reports · 12 Nov 2026 PMID 43018799
  2. Discovery and Optimization of Indole-Based CDK9 Inhibitors for Hepatocellular Carcinoma. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018595
  3. Bacteroidetes promote hepatocellular carcinoma progression and resistance to immunotherapy. Hepatology communications · 11 Nov 2026 PMID 43013741
  4. Mechanism of Coumarin in the anti-liver cancer activity by promoting NK cell activation. Medical oncology (Northwood, London, England) · 6 Oct 2026 PMID 42837059
  5. HCE6-mediated photodynamic therapy induces hepatocellular carcinoma cell death via inhibition of autophagic flux. Journal of materials chemistry. B · 18 Sept 2026 PMID 42758539
  6. HIF1α-KLF4 signaling dictates extra-erythrocyte expression of hemoglobin conferring sorafenib resistance in hepatocellular carcinoma. Signal transduction and targeted therapy · 15 Sept 2026 PMID 42744801
  7. p-Coumaric acid inhibits hepatocellular carcinoma through promoting ROS accumulation. Medical oncology (Northwood, London, England) · 10 Sept 2026 PMID 42720830
  8. Decoding neoantigen-encoding tumor-specific transcripts unveils a shared target reservoir for immunotherapy in hepatocellular carcinoma. Journal for immunotherapy of cancer · 21 Jul 2026 PMID 42481156
  9. Dark tea-derived exosome-like nanovesicles suppress hepatocellular carcinoma via inhibiting Akt pathway and modulating immune profiles. Phytomedicine : international journal of phytotherapy and phytopharmacology · 9 Jul 2026 PMID 42424676
  10. Valence-activated arsenic nanozyme enables cascade-amplified chemodynamic therapy for hepatocellular carcinoma. International journal of pharmaceutics · 25 Jun 2026 PMID 42349733
  11. FeCo Dual-Atom Site Nanozyme Hybrid Microneedle Patch with Enhanced Multienzyme Mimetic Activities for Synergistic Antihepatoma Therapy. ACS applied materials & interfaces · 23 Jun 2026 PMID 42333601
  12. Artificial Gap Junctional Channel Inhibiting the Proliferation of Hepatocellular Carcinoma Cells. Angewandte Chemie (International ed. in English) · 7 Jun 2026 PMID 42251683
  13. β,β-Dimethylacrylshikonin suppresses hepatocellular carcinoma progression through mitochondrial stress and TGM2-associated mitophagy impairment. Phytomedicine : international journal of phytotherapy and phytopharmacology · 23 May 2026 PMID 42176510
Unclassified: not yet indexed with MeSH (2)
  1. Multi-omics and spatial transcriptomics reveal that S100A10 drives CD8+ T-cell exhaustion and immune evasion in hepatocellular carcinoma through cPLA2-5-LOX-mediated arachidonic acid metabolism and ferroptosis. International immunopharmacology · 13 Sept 2026 PMID 42732672
  2. Multi-omics and artificial intelligence nominate PCLAF as a prognostic and druggable target for hepatitis B virus-associated hepatocellular carcinoma. Cellular signalling · 22 Jul 2026 PMID 42486346